In a report issued on February 24, Bill Sutherland from Benchmark Co. maintained a Buy rating on Amedisys (AMED – Research Report), with a price target of $175.00. The company’s shares closed last Friday at $159.90.
According to TipRanks.com, Sutherland is a 1-star analyst with an average return of -3.0% and a 39.3% success rate. Sutherland covers the Healthcare sector, focusing on stocks such as Select Medical, HeartBeam, and UpHealth.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amedisys with a $195.20 average price target, representing a 30.9% upside. In a report issued on February 25, BMO Capital also upgraded the stock to Buy with a $190.00 price target.
Amedisys’ market cap is currently $5.2B and has a P/E ratio of 25.23.
Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AMED in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The company was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.
Read More on AMED: